SCHEMBL20133161

SCHEMBL20133161

CC(C)(C)OC(=O)N1CCC(OCCOCCCOCc2ccccc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STS P08842 1/20 0.50
GPR119 Q8TDV5 3/20 0.49
KDM4E B2RXH2 1/20 0.47
PKM P14618 1/20 0.47
PRMT5 O14744 2/20 0.47
WDR77 Q9BQA1 1/20 0.47
LIPG Q9Y5X9 1/20 0.46
KEAP1 Q14145 1/20 0.46
NFE2L2 Q16236 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
GAA P10253 1/20 0.46
THRB P10828 1/20 0.46
JAK2 O60674 1/20 0.45
JAK1 P23458 1/20 0.45
YAP1 P46937 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
TEAD3 Q99594 1/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HTT P42858 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21458404 0.98 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL22906856 0.98 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL34464873 0.98 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL21458929 0.98 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL21458596 0.97 STS (0.53) STSGPR119KDM4EPKMPRMT5
SCHEMBL30750608 0.96 STS (0.50) STSGPR119KDM4EPKMPRMT5
SCHEMBL31303428 0.96 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL20133355 0.94 STS (0.51) STSGPR119KDM4EPKMPRMT5
SCHEMBL13096781 0.93 STS (0.52) STSGPR119KDM4EPKMPRMT5
SCHEMBL20133160 0.92 STS (0.47) STSGPR119KDM4EPKMPRMT5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2021011913-A1 TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. (US) 2021-01-21 WO disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN STS 4758/4885GPR119 3791/4885KDM4E 1112/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 STS 4487/4885GPR119 3741/4885KDM4E 1212/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.